-
Start Preamble
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 25, 2001, Dupont Pharmaceuticals, 1000 Stewart Avenue, Garden City, New York 11530, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Oxycodone (9143) II Hydrocodone (9193) II Oxymorphone (9652) II The firm plans to manufacture the listed controlled substances to make finished products.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections tot he issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than December 10, 2001.
Start SignatureDated: October 2, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 01-25443 Filed 10-10-01; 8:45 am]
BILLING CODE 4410-09-M
Document Information
- Published:
- 10/11/2001
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 01-25443
- Pages:
- 51969-51969 (1 pages)
- PDF File:
- 01-25443.pdf